Management of polycystic ovarian syndrome with Diane-35 or Diane-35 plus metformin

References

• Norman RJ, Dewailly D, Legro RS, Hickey TE. Polycystic ovary syndrome. Lancet 2007;370:685–97
   PubMed Web of Science ®Google Scholar
• Ehrmann DA. Polycystic ovary syndrome. N Engl J Med 2005;352:1223–36
   PubMed Web of Science ®Google Scholar
• Calaf J, López E, Millet A, et al. Long-term efficacy and tolerability of flutamide combined with oral contraception in moderate to severe hirsutism: a 12-month,double-blind,parallel clinical trial. J Clin Endocrinol Metab 2007;92:3446–52
   PubMed Web of Science ®Google Scholar
• Demircay Z, Kus S, Sur H. Predictive factors for acne flare during isotretinoin treatment. Eur J Dermatol 2008;18:452–6
   PubMed Web of Science ®Google Scholar
• Thessaloniki ESHRE/ASRM-Sponsored PCOS Consensus Workshop Group. Consensus on infertility treatment related to polycystic ovary syndrome. Fertil Steril 2008;89:505–22
   PubMed Web of Science ®Google Scholar
• Baptiste CG, Battista MC, Trottier A, Baillargeon JP. Insulin and hyperandrogenism in women with polycystic ovary syndrome. J Steroid Biochem Mol Biol 2010;122:42–52
   PubMed Web of Science ®Google Scholar
• Domecq JP, Prutsky G, MullanR J. Lifestyle modification programs in polycystic ovary syndrome: systematic review and meta-analysis. J Clin Endocrinol Metab 2013;98:4655–63
   PubMed Web of Science ®Google Scholar
• Yildiz BO, Knochenhauer ES, Azziz R. Impact of obesity on the risk for polycystic ovary syndrome. J Clin Endocrinol Metab 2008;93:162–8
   PubMed Web of Science ®Google Scholar
• Moran LJ, Hutchison SK, Norman RJ, Teede HJ. Lifestyle changes in women with polycystic ovary syndrome. Cochrane Database Syst Rev 2011;2:CD007506
   Google Scholar
• Hardiman P, Pillay OC, Atiomo W. Polycystic ovary syndrome and endometrial carcinoma. Lancet 2003;361:1810–12
   PubMed Web of Science ®Google Scholar
• Chittenden BG, Fullerton G, Maheshwari A, Bhattacharya S. Polycystic ovary syndrome and the risk of gynaecological cancer: a systematic review. Reprod Biomed Online 2009;19:398–405
   PubMed Web of Science ®Google Scholar
• Caruso S, Cianci S, Malandrino C, et al. Hyperandrogenic women treated with a continuous-regimen oral contraceptive. Eur J Obstet Gynecol Reprod Biol 2013;171:307–10
   PubMed Web of Science ®Google Scholar
• Rotterdam ESHRE/ASRM-Sponsored PCOS Consensus Workshop Group. Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome (PCOS). Hum Reprod 2004;19:41–7
   PubMed Web of Science ®Google Scholar
• Ferriman D, Gallwey JD. Clinical assessment of body hair growth in women. J Clin Endocrinol Metab 1961;21:1440–7
   PubMed Web of Science ®Google Scholar
• Jing Z, Liang-Zhi X, Tai-Xiang W, et al. The effects of Diane-35 and metformin in treatment of polycystic ovary syndrome: an updated systematic review. Gynecol Endocrinol 2008;24:590–600
   PubMed Web of Science ®Google Scholar
• Odicino F, Pecorelli S, Zigliani L, Creasman WT. History of the FIGO cancer staging system. Int J Gynaecol Obstet 2008;101:205–10
   PubMed Web of Science ®Google Scholar
• Legro RS, Zaino RJ, Demers LM, et al. The effects of metformin and rosiglitazone, alone and in combination, on the ovary and endometrium in polycystic ovary syndrome. Am J Obstet Gynecol 2007; 196:e401–10
   Google Scholar
• Lord J, Thomas R, Fox B, et al. The central issue? Visceral fat mass is a good marker of insulin resistance and metabolic disturbance in women with polycystic ovary syndrome. BJOG 2006;113:1203–9
   PubMed Web of Science ®Google Scholar
• Gallo MF, Lopez LM, Grimes DA, et al. Combination contraceptives: effects on weight. Cochrane Database Syst Rev 2014;1:CD003987
   PubMedGoogle Scholar
• Glintborg D, Altinok ML, Mumm H, et al. Body composition is improved during 12 months treatment with metformin alone or combined with oral contraceptives compared to treatment with oral contraceptives in polycystic ovary syndrome. J Clin Endocrinol Metab 2014;17:jc20141135
   Google Scholar
• Kahraman K, Sükür YE, Atabeko CS, et al. Comparison of two oral contraceptive forms containing cyproterone acetate and drospirenone in the treatment of patients with polycystic ovary syndrome: a randomized clinical trial. Arch Gynecol Obstet 2014;290:321–8
   PubMed Web of Science ®Google Scholar
• Rautio K, Tapanainen JS, Ruokonen A. Effects of metformin and ethinyl estradiol-cyproterone acetate on lipid levels in obese and non-obese women with polycystic ovary syndrome. Eur J Endocrinol 2005;152:269–75
   PubMed Web of Science ®Google Scholar
• Wu J, Zhu Y, Jiang Y. Effects of metformin and ethinyl estradiol-cyproterone acetate on clinical, endocrine and metabolic factors in women with polycystic ovary syndrome. Gynecol Endocrinol 2008;24:392–8
   PubMed Web of Science ®Google Scholar
• Orbetsova M, Kamenov Z, Kolarov G. Effect of 6-month treatment with oral antiandrogen alone and in combination with insulin sensitizers on body composition, hormonal and metabolic parameters in women with polycystic ovary syndrome(PCOS) in order to determine therapeutic strategy. Akush Ginekol (Sofiia) 2006;45:16–28
   PubMedGoogle Scholar